Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SABSW
SABSW | US
0.02
USD0
0%
SABSW | US
Loading StockChartView...
About SABSW
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
0.02
Open
0.02
High
0.02
Low
0.02
SAB Biotherapeutics Inc. a clinical-stage biopharmaceutical company engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185 a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176 a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection; and SAB-181 for immune globulin (IgG) mediated diseases. It focuses on infectious diseases such as COVID-19 and influenza immune system disorders comprising type 1 diabetes organ transplantation and cancer. The company was founded in 2014 and is based in Miami Beach Florida.
View LessSABSW | US
Risk
323.9
Sharpe
-0.09
Luna's Score
51/100
Recommendation
Hold
Luna says (SABSW | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
480.7%1 month
323.9%3 months
219.0%6 months
260.7%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
0.17
Fwd. PE
-
Price to book
-
Debt to equity
0.12
Debt to assets
0.09
Ent. to EBITDA
-
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-40.91M
MarketCap
-
MarketCap(USD)
-
Div. yield
-
Op. margin
-3.88K
Erngs. growth
-
Rev. growth
207.70
Ret. on equity
-122.49
Short ratio
-
Short perc.
-
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.01
Range1M
0.01
Range3M
0.04
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.01
Price X volume
2.04
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | - | 0.53 | - |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | 0.17 | 41.03 | Cheaper |
| Price to Book | - | 15.55 | - |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 218.99 | 72.80 | Riskier |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.09 | 0.25 | Cheaper |
| Market Cap | - | 3.66B | - |
